A serine/threonine kinase SAD-1 in C. elegans regulates synapse development. We report here the isolation and characterization of mammalian orthologs of SAD-1, named SAD-A and SAD-B, which are specifically expressed in the brain. SAD-B is associated with synaptic vesicles and, like the active zone proteins CAST and Bassoon, is tightly associated with the presynaptic cytomatrix in nerve terminals. A short conserved region (SCR) in the COOH-terminus is required for the synaptic localization of SAD-B. Overexpression of SAD-B in cultured rat hippocampal neurons significantly increases the frequency of miniature excitatory postsynaptic current but not its amplitude. Introduction of SCR into presynaptic superior cervical ganglion neurons in culture significantly inhibits evoked synaptic transmission. Moreover, SCR decreases the size of the readily releasable pool measured by applying hypertonic sucrose. Furthermore, SAD-B phosphorylates the active zone protein RIM1 but not Munc13-1. These results suggest that mammalian SAD kinase presynaptically regulates neurotransmitter release.
Introduction
Neurotransmitter release is mediated by exocytosis in a temporally and spatially coordinated manner. In the classical synaptic vesicle (SV) cycling pathway, SVs filled with appropriate neurotransmitters are reserved as a pool, the reserve pool, and are transported to the active zone specialized for exocytosis (Sü dhof, 1995) . SVs, docked to the active zone and undergoing a prefusion step or priming, are ready for vesicle fusion and release of neurotransmitters (Sü dhof, 1995) . These SVs are thought to compose a vesicle pool distinguished as the readily releasable pool (RRP) (Birks and MacIntosh, 1961) . After completion of these steps, SV proteins and membrane components are retrieved by endocytosis through clathrin-coated pits and recycled through early endosomes (Cremona and De Camilli, 1997; Hay and Scheller, 1997) . SVs are the key organelle in this process of vesicle cycling, and numerous SV proteins have been isolated and characterized (Sü dhof, 1995; Sü dhof, 2004) . But, it is still tempting to speculate that other regulatory proteins remain to be identified in SV docking, priming, and fusion.
The active zone beneath the presynaptic membrane is the principal site for Ca 2+ -dependent exocytosis (Landis et al., 1988) . It has been assumed that the cytomatrix at the active zone (CAZ) is involved in determining the site of SV fusion, but molecular mechanisms by which SVs properly localize at the CAZ remain elusive. Presently, the full molecular composition of the CAZ is unclear, but several CAZ proteins, including CAST/ERC2, ELKS, RIM1, Munc13-1, Piccolo/Aczonin, and Bassoon, are known (Brose et al., 1995; Wang et al., 1997; tom Dieck et al., 1998; Wang et al., 1999; Fenster et al., 2000; Ohtsuka et al., 2002; Wang et al., 2002; TakaoRikitsu et al., 2004) . RIM1 and Munc13-1 directly bind to each other and are implicated in SV priming (Betz et al., 2001) . Bassoon and Piccolo are very large proteins structurally related to each other, and Bassoon has been shown to be involved in neurotransmitter release at excitatory synapses . CAST and ELKS are novel active zone proteins highly homologous to each other, which directly bind RIMs, Bassoon, and Piccolo, and thought to play a role in neurotransmitter release by binding these active zone proteins (Ohtsuka et SAD-1 in C. elegans was first identified by genetic screens to isolate mutations that affect SV clusters in sensory neurons (Crump et al., 2001) . Indeed, the sad-1 mutant animal shows several unique features in its synaptic structure and function, such as the diffuse and disorganized distribution of SVs at synapses and a failure to develop normal synapses in sensory axons. Most mutations occur in the kinase domain, suggesting that this domain of SAD-1 may play an important role in the formation of synapses. Recently, KO mice for SAD-1 orthologs (SAD kinases) have been reported (Kishi et al., 2005) . Analysis of the mutant animals shows that mammalian SAD kinases are required for neural polarity that produces axons and dendrites with distinct properties, which is promoted at least in part by phosphorylating the microtubule-associated protein Tau (Kishi et al., 2005) . Although these genetic studies have revealed that SAD kinases regulate various aspects of early synapse development, the biochemical properties and the physiological functions of SAD kinases at mature synapses remain largely unknown.
To test if SAD-1 is also involved in synaptic functions such as neurotransmitter release in vertebrates, we had isolated and characterized human orthologs of SAD-1. Human SAD-1 comprised at least two family members, tentatively named SAD-A and SAD-B, both of which were specifically expressed in the brain. In the present study, we demonstrate that SAD kinase is a novel SVand presynaptic cytomatrix-associated protein that regulates neurotransmitter release at mature synapses.
Results

Molecular Cloning of the SAD-1 cDNAs
To isolate a mammalian ortholog of C. elegans SAD-1, we first searched the GenBank database with the primary sequence of SAD-1 and found several cDNA fragments that were homologous to SAD-1 cDNA (data not shown). By screening a human cDNA library, we obtained two full-length cDNAs, and named them SAD-A and SAD-B. Although SAD-A consisted of 696 aa with a calculated molecular weight of 77,597, SAD-B consisted of 778 aa with a calculated molecular weight of 85,086. Both SAD-A and SAD-B had similar domain organizations to that of C. elegans SAD-1 ( Figure 1A ). The NH 2 -terminal serine/threonine kinase (STK) domain was well conserved and almost identical between SAD-A and SAD-B (94% identity). In addition, two short conserved regions (SCR1 and SCR2) (Crump et al., 2001) existed in the middle and COOH-terminal regions.
Tissue Distribution of SAD-B Northern blot analysis showed that the w3.5 kb band of SAD-B was specifically detected in the brain (Figure S1A ). SAD-A was also specifically expressed in the brain (data not shown). Both the proteins were structurally related to each other and specifically expressed in the brain, and then we focused on SAD-B. We next produced a polyclonal antibody (Ab) against SAD-B that specifically detected SAD-B, but not SAD-A (Figure S1B) . Tissue distribution analysis showed that the anti-SAD-B Ab recognized a protein band of w90 kDa in rat brain, but not in other rat tissues ( Figure 1B ), indicating that SAD-B is specifically expressed in the brain.
Localization of SAD-B at Synapses
Western blotting revealed that SAD-B was expressed in various rat brain regions, including the hippocampus, the cortex, the cerebellum, the amygdala, and the olfactory bulb (data not shown). Consistently, a widespread immunoreactivity for SAD-B was detected throughout mouse brain ( Figure S1C ). We then examined in more detail the localization of SAD-B in mouse hippocampus and cerebellum by immunohistochemistry and compared the staining pattern of SAD-B with that of synaptophysin. In the CA3 region of the hippocampus, the immunofluorescence signal for SAD-B overlapped with that of synaptophysin ( Figure 1C ). In the cerebellum, SAD-B showed a similar signal pattern in the molecular and granular cell layers, which colocalized with that of synaptophysin ( Figure 1D ). Note that the signal of SAD-B was also detected in the cell bodies. These results suggest that SAD-B is relatively concentrated and localized at the synapses.
In primary cultured rat hippocampal neurons, SAD-B showed a dot-like signal along the dendrites that colocalized well with that of synaptophysin, although immunoreactivity of SAD-B was slightly detected in the cell body and dendrites (Figure 1E, top) . In addition, the signal for SAD-B partially colocalized with those of the active zone protein Bassoon and the well-known postsynaptic density (PSD) protein PSD-95/SAP90 (Cho et al., 1992; Kistner et al., 1993) (Figure 1E , middle and bottom). These results also support the notion that SAD-B is a synaptic protein.
Association of SAD-B with Synaptic Vesicles and the Presynaptic Cytomatrix
We used immunoelectron microscopy to examine the subsynaptic localization of SAD-B. Immunoelectron microscopic analysis of cultured neurons showed that immunogold-labeled signals of SAD-B were mainly detected in presynaptic nerve terminals (Figure 2A ). The signal of SAD-B appeared to be associated with SVs. Interestingly, some of the signals were detected very close to the presynaptic plasma membrane. Note that several signals of SAD-B were also detected in the dendrites ( Figure 2A ) and cell bodies (data not shown). These results further support the notion that SAD-B is mainly present in the presynaptic nerve terminals.
Consistent with these results, subcellular distribution analysis in rat brain showed that SAD-B was relatively concentrated in the crude synaptic vesicle (CSV) fraction ( Figure 2B ), which was similar to that for synaptophysin. Further fractionation of the CSV fraction produced SV1-SV4 fractions, of which the SV1 fraction contains the most pure sample of SVs (Mizoguchi et al., 1989) . SAD-B and synaptophysin were mainly detected in the SV1 and SV2 fractions ( Figure 2C ). In addition, the SVs immunoisolated by an anti-synaptotagmin I Ab contained synaptophysin and SAD-B ( Figure 2D , left). Under the same conditions, the SVs immunoisolated by the anti-SAD-B Ab contained synaptophysin and synaptotagmin I ( Figure 2D, right) . Therefore, these results suggest that SAD-B is an SV-associated protein.
In addition, SAD-B and synaptophysin were detected in the crude synaptic membrane (CSM) fraction (Figure 2B) , suggesting that both proteins were associated with docked SVs. Moreover, like the active zone protein CAST and the PSD protein NMDA receptor, SAD-B was concentrated in the biochemically isolated PSD fraction, whereas synaptophysin was almost completely absent from this fraction ( Figure 2B ). The biochemically isolated PSD fraction is known to contain not only PSD proteins but also the active zone proteins CAST, RIMs, Bassoon, and Piccolo (Cases-Langhoff et al., 1996; Langnaese et al., 1996; Wang et al., 1997; tom Dieck et al., 1998; Phillips et al., 2001; Ohtsuka et al., 2002) . Thus, the signal of SAD-B in the PSD fraction appears to correspond to that of SAD-B, which localized close to the presynaptic membrane (see Figure 2A ). In addition, SAD-B was resistant to solubilization by CHAPS, a zwitter ionic detergent, and NP-40 and Triton X-100, nonionic detergents, in contrast to synaptophysin (Figure 2e ). This biochemical property of SAD-B was similar to those of the CAZ proteins CAST ( Figure 2E , bottom) (Ohtsuka et al., 2002) , RIM1, Bassoon, and Piccolo. But, unlike CAST, SAD-B was slightly solubilized with the nonionic detergents, which might be at least partly consistent with the immunorectivity for SAD-B in the cell bodies and dendrites of neurons (see Figures 1E and 2A ) and its association with SVs. At any rate, these results suggest that some portions of SAD-B are tightly associated with the presynaptic cytomatrix.
We next performed a cell biological analysis to confirm the tight association of SAD-B with the presynaptic cytomatrix. To do this, we briefly treated cultured neurons with Triton X-100 before paraformaldehydefixation and then stained synaptic proteins such as synaptophysin, SAD-B, CAST, and Bassoon. Under such conditions, synaptophysin, a Triton X-100-soluble SV protein, was shown to be almost completely extracted, whereas Bassoon was hardly extracted (Dresbach et al., 2003) . Consistent with these observations, synaptophysin was completely washed out ( Figure 3A) , whereas Bassoon was preserved ( Figure 3B ). Like Bassoon, another prominent CAZ protein CAST was also preserved ( Figures 3A and 3B ). Under the same conditions, SAD-B was indeed preserved like these CAZ Figure 2 . Subcellular Distribution of SAD-B in Neurons (A) Immunoelectron microscopy. Neurons were reacted with the anti-SAD-B Ab, incubated with immunogold particles (1.4 nm) conjugated with goat IgG against rabbit IgG and silver-enhanced, followed by electron microscopic analysis. Bars, 500 nm. (B) Subcellular distribution. The homogenate of rat brain was subjected to subcellular fractionation. An aliquot of each fraction (5 mg of protein each) was analyzed by Western blotting with the indicated Abs. Hom, homogenate; S1, crude synaptosomal fraction; P2, crude membrane fraction; P2A, myelin fraction; P2B, ER, Golgi complex and membranes fraction; P2C, synaptosomal fraction; P2D, mitochondria fraction; CSV, crude synaptic vesicle fraction; CSM, crude synaptic membrane fraction; PSD, postsynaptic density fraction; S, 1% Triton X-100-soluble fraction of PSD; P, 1% (w/v) Triton X-100-insoluble fraction of PSD. NMDAR2, the NMDA receptor 2B; Syn, synaptophysin. (C) Subcellular distribution in the CSV fraction. An aliquot of each fraction (2 mg of protein each) was analyzed by Western blotting with the indicated Abs. SV1, contained SVs almost free synaptic plasma membranes; SV2, contained SVs contaminated with some synaptic plasma membranes; SV3, contained mainly synaptic plasma membranes contaminated with SVs; SV4, contained synaptic plasma membranes with almost free SVs. Sytx, Syntaxin1A. (D) Immunoaffinity purification of SAD-B-associated vesicle. The vesicle fraction was immunoaffinity purified with anti-Myc, anti-synaptotagmin I, control rabbit IgG, or anti-SAD-B Ab from P2 fraction. Each immunoaffinity-purified fraction was analyzed by Western blotting with the indicated Abs. StgI, synaptotagmin I. (E) Solubility of SAD-B, synaptophysin, and CAST by various detergents. Proteins were extracted from the crude membrane fraction with the indicated detergents and then separated into the soluble and pellet fractions. An aliquot (10 ml) of each fraction was analyzed by Western blotting with the indicated Abs. P, pellet fraction; S, soluble fraction. The results are representative of three independent experiments. proteins ( Figures 3C and 3D ). Moreover, immunoelectron microscopic analysis with these Triton X-100-treated cultured neurons revealed that SAD-B was associated with the presynaptic cytomatrix ( Figure 3E ). These results suggest that SAD-B is associated with SVs and incorporated into and tightly associated with the presynaptic cytomatrix.
Mechanism of Localization of SAD-B in Neurons
We next examined the mechanism of the localization of SAD-B in primary cultured rat hippocampal neurons by expressing their various mutants. The various SAD-B mutants are schematically shown in Figure 4A . We first expressed the full-length of SAD-B. EGFP-SAD-B-1 colocalized with synaptophysin at the synaptic boutons ( Figure 4B ). EGFP-SAD-B-2, which had only the STK domain, showed diffuse distribution in cultured neurons (data not shown). In contrast, EGFP-SAD-B-4, which lacked the STK domain but had two SCRs, colocalized with synaptophysin ( Figure 4B ). EGFP-SAD-B-5, which lacked the STK domain but had SCR2, colocalized with synaptophysin (data not shown). EGFP-SAD-B-6, which had SCR2, colocalized with synaptophysin, whereas EGFP-SAD-B-3, which lacked the COOH terminus containing SCR2, showed a diffuse distribution (Figure 4B) . These results suggest that SAD-B synaptically localizes in cultured neurons through its COOH-terminal region containing SCR2.
Involvement of SAD-B in Neurotransmitter Release in Primary Cultured Rat Hippocampal Neurons
The unique localization of SAD-B on SVs and at the presynaptic cytomatrix suggests that SAD-B is involved in neurotransmitter release in the nerve terminals. To test this, we examined the role of SAD-B in neurotransmission by transfection of the SAD-B constructs in primary cultured rat hippocampal neurons, followed by electrophysiological studies. The kinase domain of SAD-B belongs to those of other STKs such as cAMPKa and MARK1 (Hanks et al., 1988; Drewes et al., 1997) . In these kinases, a conserved lysine residue located in the ATP binding site is essential for their kinase activity (Hanks et al., 1988) . In fact, the substitution of the lysine residue to arginine abolishes the kinase activity of these kinases (Drewes et al., 1997; Zhong et al., 1997) . This lysine residue is also conserved as lysine 63 in SAD-B ( Figure 5A ). We thus substituted the lysine residue of SAD-B to the arginine residue ( Figure 5A ) to obtain a kinase-deficient mutant of SAD-B (EGFP-SAD-B-1 K63R ) (see Figure 8 ).
After transfecting the cultured neurons with EGFP-SAD-B-1 wild and EGFP-SAD-B-1 K63R , we measured miniature excitatory postsynaptic current (mEPSC) by blocking sodium-channel-mediated action potential activity with tetrodotoxin (TTX) under whole-cell voltage clamp. Overexpression of EGFP-SAD-B-1 significantly increased the frequency of mEPSC by approximately 6-fold (n = 8 for EGFP-SAD-B-1, EGFP-SAD-B-1 versus control, p < 0.01), whereas control EGFP or EGFP-SAD-B-1 K63R had no effect on the frequency (Figures 5B and 5C) . No significant change of its amplitude was observed by overexpression of all the constructs (Figure 5D ). In addition, no significant difference in the average rise time and decay time of mEPSC was detected (data not shown), suggesting that SAD-B may not be involved in the fusion of SVs.
It is possible that the absence of significant effects on mEPSC frequency upon overexpression of dominantnegative EGFP-SAD-B-1 K63R might be due to the low basal level of spontaneous transmitter release occurring at a normal Ca 2+ concentration ( Figures 5B and 5C ). We then performed the same experiment at 10 mM external Ca 2+ , which enhanced basal mEPSC frequencies. Although no significant change in amplitude, rise time, or decay time was observed under these conditions (data not shown), the mEPSC frequency was increased w1.8-fold by overexpression of EGFP-SAD-B-1 wild (n = 11 for EGFP-SAD-B-1 wild versus control, p < 0.01) and was significantly decreased by overexpression of EGFP-SAD-B-1 K63R (w0.6-fold) ( Figure 5E and 5F). These results suggest that the SAD-B kinase activity is involved in the regulation of SV release probability. To confirm neurotransmitter specificity of the observed effects, mEPSCs were abolished with 50 mM CNQX (data not shown), indicating that SAD-B regulates AMPA receptor-mediated neurotransmission by a presynaptic mechanism.
Because SAD-1 in C. elegans has been shown to be involved in synapse formation, such as the clustering of SVs (Crump et al., 2001) , we examined whether such a developmental effect may be a basis for the SAD-B function in neurotransmitter release. We coexpressed SAD-B with synaptophysin-EGFP or EGFP-Bassoon and examinined the change of the size and number of the EGFP and endogenous signal: we assumed that the staining signals for synaptophysin and Bassoon reflect those of SVs and active zones, respectively. A quantitative analysis showed no significant change in the size and number of synaptophysin or Bassoon immunoreactive puncta (Figures S3 and S4 ). Thus, developmental changes do not appear to contribute to the SAD function in neurotransmitter release.
Mechanism of Action of SAD-B in Neurotransmitter Release
We next examined the mode of action of SAD-B at a well-characterized cholinergic synapse formed between cultured rat superior cervical ganglion (SCG) neurons (Mochida et al., 1994 (Mochida et al., , 1995 (Mochida et al., , 1996 Ilardi et al., 1999) . This is an ideal system because proteins can be introduced into the relatively large (30-40 mm) presynaptic cell bodies by microinjection, the injected proteins can rapidly diffuse to nerve terminals forming synapses with adjacent neurons, and the effect on stimulated release of acetylcholine can be accurately monitored by recording excitatory postsynaptic potentials (EPSPs) evoked by action potentials in presynaptic neurons. In SCG neurons, SAD-B showed dot-like signals that colocalized well with those of synaptophysin and Bassoon ( Figure S2 ), indicating that SAD-B localizes at synapses formed between cultured SCG neurons, together with other synaptic proteins.
To test the presynaptic function of SAD-B in this system, we then prepared the recombinant protein of SCR2, which might affect SAD-B function in neurons, because this region appears to play a role in localizing SAD-B at synapses in neurons (Figure 4 ). In addition we prepared another GST-tagged protein, as a control, from an unconserved region (S1) (aa 450-521), which is located between SCR1 and SCR2 in SAD-B. Microinjection of SCR2 into presynaptic SCG neurons significantly inhibited synaptic transmission ( Figures 6A, 6B , 6F, and 6G), without changing EPSP waveform ( Figure 6A ). The amplitude of EPSP recorded every 20 s at 0.05 Hz decreased by 236 6 8.3% (n = 5) at 70 min after injection of SCR2. In contrast, neither the S1 nor GST, as a control, produced any significant decrease in the EPSP amplitude ( Figures 6D and 6E ) (21.7 6 5.6%, n = 5, and 24.4 6 8.1%, n = 5, respectively) (p < 0.01 unpaired t test at 70 min after the injection of SCR2 versus S1 or GST). The decrease in EPSP amplitude by SCR2 (1 or 10 mM) recovered to control preinjection levels within 80 min ( Figures 6H and 6I) , indicating that the SCR2 effect was concentration dependent and reversible. Next, we raised a polyclonal Ab against the SCR2 domain of SAD-B and microinjected the IgG fraction into SCG neurons. The anti-SCR2 Ab specifically impaired neurotransmission, whereas control rabbit IgG had no effect ( Figure 6J ). Taken together, these results provide functional evidence that SCR2 of SAD-B may play a role in neurotransmitter release.
We examined the possible involvement of SAD-B in an SV-trafficking step regulating the RRP. To test this, we accelerated the cycling of SVs in presynaptic terminals by employing presynaptic stimulation with a higher frequency. Stimuli at 0.2 Hz produced no significant potentiation of the SCR2-dependent reduction in EPSP ( Figure 6C ). At 70 min after the injection of SCR2, the EPSP amplitude was reduced by 234 6 7.8% (n = 5). This value, a decrease of 34%, was not significantly different from the 36% reduction with 0.05 Hz stimulation (p = 0.48, unpaired t test at 70 min after the injection of SCR2 with 0.2 Hz versus 0.05 Hz stimulation). In another series of experiments, repetitive stimulation (0.05 Hz) was stopped for 20 min after injection of SCR2. When stimulation was started again, the EPSP amplitude was smaller than that observed before stimulation was interrupted ( Figures 6K and 6L) . These results suggest that the reduction of neurotransmitter release by injection of SCR2 is independent of presynaptic firing history or the activity-dependent cycling of SVs in presynaptic nerve terminals. Next, we employed a paired-pulse stimulation protocol to ask whether SCR2 interferes with the releasable vesicles at the active zone within short interstimulus intervals of neurotransmitter release (Stevens and Wang, 1995) elicited by successive evoked action potentials. In this experiment, EPSPs evoked with various time intervals between two action potentials were recorded both before and 15-35 min after SCR2 injection. The amplitudes of the first and the second EPSP were reduced after SCR2 injection in the absence of presynaptic activity ( Figures 7A and 7B ). In the presence of SCR2, the second EPSP amplitude did not recover to the initial amplitude ( Figures 7B and 7C ). These results suggest that SCR2 perturbations reduce the amount of releasable transmitter at the active zone independently of the presynaptic activity and the amount of secondary releasable transmitter within a short interval, indicating that the major effect of SCR2 most likely involves a step specifying the number, priming, or sensitivity of vesicles in the RRP at the active zone, and/or release probability and quantal size (Chen et al., 2004) .
To confirm the role of SAD-B in regulation of the RRP, we examined the effect of SAD-B on the size of the RRP. In this experiment, we repeatedly applied hypertonic sucrose solution to selectively release the functionally defined RRP (Rosenmund and Stevens, 1996) . Focal puffapplication of 0.5 M sucrose to a synaptic pair induced small EPSPs in postsynaptic neurons ( Figure 7D ). The integral value of the small EPSPs with hypertonic challenge reflects the size of the RRP ( Figure 7D) ; and therefore, changes in the integral value indicate changes in the size of the RRP (Figures 7E and 7F) . Injection of SCR2 reduced the integral by 225 6 8.4% (n = 7) at 27 min after starting SCR2 injection (p < 0.03, paired t test before versus at 27 min after the injection). As a control, S1 produced no significant reduction of the small EPSPs integral (p = 0.39, paired t test before versus at 27 min), suggesting that the decrease in size of the RRP by the SCR2 is specific (p < 0.05, unpaired t test at 27 min after SCR2 versus S1 injection). Taken together, these results suggest that SAD-B is involved in control of the RRP size.
Kinase Activity of SAD-B
The findings so far led us to speculate that SAD kinase might phosphorylate a substrate(s) in the nerve terminal for regulation of neurotransmitter release. Such candidates would be the active zone protein/vesicle priming factor RIM1 and/or Munc13-1, because these active zone proteins directly interact with each other and are involved in the priming step during neurotransmitter release (Betz et al., 2001) , and SAD-B is associated with the presynaptic cytomatrix at the active zone (in this study). Thus, to examine whether SAD kinase phosphorylates RIM1 and Munc13-1, we first attempted to characterize the kinase activity of SAD-B. For this, we overexpressed Myc-tagged full-length of SAD-B (Myc-SAD-B wild or K63R ; see Figure 5A ) into HEK293 cells. As shown in Figure 8 ; see Figure 4A ) ( Figure 8Aa1 ).
As to the slight phosporylation of Myc-SAD-B
K63R
and -SAD-B KD K63R , we assume that this is due to the contamination of a kinase(s) in immunoprecipitation lysates from HEK293 cells, which may phosphorylate the mutant protein, causing the background. To clarify this issue, we employed two approaches. First, we produced another mutant of SAD-B in which threonine 189 and serine 193 were substituted to alanine. These residues were conserved in the related kinase PAR1/ MARK and shown to be autophosphorylated (Drewes et al., 1997) . Indeed, the mutant of SAD-B (Myc-SAD-B KD T189A/S193A ) was not phosphorylated (Figure 8Aa2 ). Second, we produced the maltose binding protein (MBP)-tagged kinase domain of SAD-B (MBP-SAD-B KD wild and K63R ) in E. coli. MBP-SAD-B KD wild was clearly autophosphorylated, whereas MBP-SAD-B KD K63R was not ( Figure 8B ). In this case, no background was detected. These results clearly show that SAD-B has a kinase activity and the mutant is kinase-deficient and then provide another line of evidence that the kinase activity of SAD-B plays a role in neurotransmitter release (see Figure 5 ).
Phosphorylation of RIM1 by SAD-B
We next produced and purified recombinant GST-fusion proteins that cover RIM1 in overlapping fragments (fragments A-E) ( Figure 8C ). These recombinant proteins were incubated with 32 P-g-ATP and MBP-SAD-B KD wild or -SAD-B KD K63R and were subjected to SDS-PAGE, followed by autoradiography and Coomassie Brilliant Blue staining ( Figure 8D ). Under the conditions in which MBP-SAD-B KD wild , but not the MBP-SAD-B KD K63R , was autophosphorylated, GST-RIM1 containing COOH-terminal region (E2), but not the other GST-fusion proteins, was specifically phosphorylated (Figure 8D , top; Figure S5 ). To confirm this, we further divided the E2 region into five fragments ( Figure 8C ). Then, GST-RIM1 E2-1 (aa 1135-1206), but not the other fusion proteins, was phosphorylated ( Figure 8E ; Figure S6 ). These results suggest that SAD-B has a potency to phosphorylate RIM1, a region near COOH-terminal C2B domain. Moreover, we finally tested whether SAD-B phosphorylates Munc13-1, but none of the recombinant proteins that cover Munc13-1 in overlapping fragments were phosporylated ( Figure S7 ). Thus, these results suggest that SAD-B specifically phosphorylates RIM1 but not Munc13-1 at least in vitro.
Discussion
SAD Kinase as an SV-Associated Protein
The following lines of evidence led us to conclude that SAD-B is a novel SV-associated protein: (1) like the prominent SV protein synaptophysin, SAD-B is concentrated in the SV1 and SV2 fractions; (2) in the mouse hippocampus and cerebellum, SAD-B colocalizes with synaptophysin; (3) in primary cultured rat hippocampal neurons, endogenous SAD-B colocalizes with synaptophysin; (4) SAD-B is observed by electron microscopy to localize at nerve terminals and is associated with SVs; and (5) SVs immunoisolated by the anti-synaptotagmin I Ab-coupled beads contain SAD-B, and vice versa.
By transfection analysis with cultured hippocampal neurons, we show here that SCR2 may play a role in localizing SAD-B at synapses, although it remains unknown whether SCR2 is required for its association with SVs. However, if this is in the case, because SCR2 has no posttranslational modification sites, it is likely that SAD-B is associated with SVs through directly binding to a SV protein(s) on SVs via SCR2 or in a manner similar to that of synapsin; it is thought to be associated with SVs through its NH 2 -terminal domain, which directly binds phospholipid moeties of SV membranes (Hosaka et al., 1999) . Currently, we have not isolated binding proteins for SCR2, but the identification and characterization of such candidates in future research would allow further insight into the molecular mechanisms underlying the association of SAD kinase with SVs.
Tight Association of SAD Kinase with the Presynaptic Cytomatrix Our biochemical and immunofluorescence studies with pretreatment by Triton X-100 show that SAD-B is also tightly associated with the presynaptic cytomatrix. This property is similar to those of CAZ proteins, such as CAST, Bassoon, and Piccolo (Cases-Langhoff et al., 1996; tom Dieck et al., 1998; Ohtsuka et al., 2002) . Immunoelectron microscopic analysis further demonstrates that some portions of SAD-B in the nerve terminal localize to the vicinity of the presynaptic plasma membrane (Figure 2A ). Thus, our present studies suggest that SAD-B is an SV-associated protein that has the potency to localize to and be tightly associated with the presynaptic cytomatrix. To our knowledge, SAD-B is the first kinase that shows these unique biochemical features and cell biological localization at synapses. But, the mode of association of SAD-B with the presynaptic cytomatrix remains unknown as is the case for its association with SVs described above.
Involvement of SAD Kinase in Neurotransmitter Release
In the present study, we have also demonstrated that SAD-B is involved in the regulation of neurotransmitter release in mammalian neurons. Overexpression of wild and subjected to SDS-PAGE, followed by autoradiography. The amount of these recombinant proteins was confirmed by Coomassie Brilliant Blue staining in Figure S6 . Under the conditions in which GST-RIM1 E2 was phosphorylated, GST-RIM1 E2-1, but not the other recombinant proteins, was specifically phosphorylated. The phosphorylated site is located in the region (1135-1206 aa) near COOH-terminal C2B domain (C).
SAD-B increases the mEPSC frequency without affecting mEPSC amplitude recorded in primary cultured rat hippocampal neurons. Overexpression of SAD-B lacking its kinase activity decreases mEPSC frequency, supporting the conclusion that SAD-B kinase activity appears to be important for the regulation of neurotransmitter release. There may be a number of physiological and possible nonphysiological substrates for overexpressed SAD kinase. However, we identified SAD-B phosphorylation of the vesicle priming factor RIM1, but not Munc13-1. This fact would seem to indicate that SAD-B is phosphorylating substrates specifically within the neurotransmitter release apparatus with which SAD-B colocalizes. Furthermore, considering the unique localization of SAD-B at the presynaptic cytomatrix, it is possible that SAD-B is well positioned to phosphorylate RIM1 in vivo consistent with the in vitro data. These observations argue against the possibility that overexpressed SAD-B kinase might pleiotropically phosphorylate noncognate substrates resulting in changes of spontaneous mEPSC activity in cultured hippocampal neurons. We therefore believe that the effect of SAD-B overexpression on spontaneous mEPSC activity reflects a physiological function of SAD kinase in nerve terminals, namely the regulation of spontaneous activity. However, we speculate that, like other serine/ threonine kinases, SAD kinase has other targets in addition to RIM1, including candidates localizing on SVs and/or active zones. Molecular and biochemical approaches are currently under way to identify and validate additional SAD-B substrates and assess their contribution to spontaneous mEPSC activity.
The present results also suggest that SAD kinase regulates neurotransmitter release at least at a step of the docking and/or priming of SVs in presynaptic nerve terminals, which is consistent with the results presented here showing tight association of SAD-B with the presynaptic cytomatrix. Indeed, the presynaptic cytomatrix is known to contain several synaptic proteins that are involved in docking and/or priming of SVs, such as Munc18, Bassoon, RIM1, and Munc13-1 (Augustin et al., 1999; Voets et al., 2001; Schoch et al., 2002; Altrock et al., 2003) . Among these candidates, we have identified at least one substrate, the active zone protein/vesicle priming factor RIM1, that is selectively phosphorylated by SAD-B (Figure 8 and Figure S7 ). Supporting evidence that the phosphorylation of RIM1 by SAD-B is specific includes: (1) SAD-B
WT , but not SAD-B K63R , phosphorylates RIM1 in a region near the COOH-terminal C2B domain; (2) SAD-B cannot phosphorylate another active zone protein/priming factor Munc13-1; (3) SAD-B localizes at the presynaptic cytomatrix together with RIM1 and Munc13-1 in vivo; (4) SAD-B, like RIM1, is involved in the regulation of neurotransmitter release, possibly in vesicle docking and/or vesicle priming. Recently, it has been reported that PKA directly phosphorylates serine 413 of RIM1, which is critical for induction of presynaptic long-term potentiation by RIM1 at cerebellar parallel fiber synapses (Lonart et al., 2003) . However, phosphorylation of RIM1 induced by forskolin, an activator of PKA, is not as strong as that induced by okadaic acid, suggesting that RIM1 is also phosphorylated by other kinases (Lonart et al., 2003) . Based on our results, another candidate RIM1 kinase may be SAD-B. Consistent with this notion, the region of RIM1 phosphorylated by SAD-B is different from that targeted by PKA (this study; Lonart et al., 2003) . RIM1 has been shown to play multiple roles in neurotransmitter release including regulation of the RRP size, short-term plasticity, and evoked asynchronous release (Calakos et al., 2004) . However, it is still unknown how phosphorylation of RIM1 by PKA, SAD kinase, and/or other unidentified kinases contribute to RIM1 function at a molecular level. Understanding the physiological significance of phosphorylation of RIM1 by SAD kinase will allow insight into the complicated mechanisms of the late steps of neurotransmitter release regulated by RIM1 at the active zone.
We have also shown here that microinjection of SCR2 into SCG neurons causes a reduction in both overall neurotransmitter release and the size of the RRP of SVs. SCR2 appears to play a role in localizing SAD-B at synapses of presynaptic terminals (Figure 4) . Thus, we propose a scenario that abnormal localization of endogenous SAD-B and/or disruption of endogenous SAD-B interaction with unidentified protein(s) in the presence of SCR2 may result in an inability of SAD-B to properly phosphorylate substrate(s) such as RIM1 that are essential for proper maintenance of the size of the RRP. To confirm this scenario, future research should address whether the SAD-B phosphorylation site near the C2B domain of RIM1 regulates the size of the RRP and also which proteins directly bind to SCR2. Our preliminary experiments show that none of the known active zone proteins such as RIM1, Munc13-1, CAST, ELKS, and Bassoon binds to SAD-B (unpublished observations), and we have preliminary attempts to isolate a SAD-B binding protein(s) by yeasttwo hybrid method, thus far unsuccessful. Other molecular approaches and/or biochemical strategies will be employed in future research to isolate SCR2 binding proteins.
Genetic studies in C. elegans clearly demonstrate that SAD-1 regulates synapse formation, particularly synaptogenesis (Crump et al., 2001 ). More recently, KO analysis of murine SAD kinases demonstrates that SAD kinases regulate axon/dendrite polarization (Kishi et al., 2005) . As presented in Figures S3 and S4 , SAD-1 function in neurotransmitter release from mature synaptic terminals does not appear to require prior developmental changes. The discrepancy may indicate a possible function of SAD-B such that endogenous SAD kinase activity is required for axon/dendrite polarization in immature neurons but not for maintaining mature axon/ dendrite polarization in established neurons. In the absence of mature defects in axon/dendrite polarization observed under our conditions, one could argue that our studies reveal another significant function of SAD kinase, the regulation of neurotransmitter release, at mature synapses. In this regard, our findings are in agreement with conclusions derived from the functional analysis on synaptobrevin/VAMP, RIM1, and Bassoon KO mice (Schoch et al., 2001; Altrock et al., 2003; Calakos et al., 2004) . In these KO mice, neurotransmitter release is significantly impaired, whereas synapse formation and gross ultrastructure remain intact. Of course, we cannot currently rule out the possibility that a subtle developmental change might occur that could not be detected under our current experimental conditions. Furthermore, it is also currently unknown why the previously observed phenotypes in C. elegans were not replicated under our conditions, but we speculate that this could be explained by specific levels of SAD kinase overexpression, effects of endogenous SAD kinases, the difference between species, developmental roles of SAD kinases, or a lack of the appropriate signals in our neuronal culture system that may be present at whole animal levels.
In summary, we have demonstrated that SAD-B, a novel SV-and active zone cytomatrix-associated protein kinase, is involved in the regulation of neurotransmitter release, perhaps via phosphorylation of the active zone protein and vesicle priming factor RIM1. Given the results presented in this paper, it is likely that SAD kinase regulates not only neurotransmitter release, but also formation of the active zone itself via phosphorylation of other crucial components for active zone assembly. In addition, SAD kinase is involved in neuronal polarization during development (Kishi et al., 2005) , although the relationship of this function to the regulation of neurotransmitter release in adult neurons described here remains to be determined. Thus, the identification and functional characterization of candidate effector substrates as well as upstream activators for SAD kinase will likely shed new light on our understanding of regulatory mechanisms governing the structure and function of the presynaptic active zone in both developing and mature neurons.
Experimental Procedures
Molecular Cloning of SAD-A and SAD-B Partial cDNA sequences of human SAD-A (AJ006701) and human SAD-B (AB058714) were identified in the EST database by a BLAST search with C. elegans SAD-1 kinase sequence. The cDNA probes for human SAD-A (bp 214-734) and were cloned from a human brain total RNA by RT-PCR with oligonucleotides designed based on the human sequences. To obtain full-length SAD-A and SAD-B, we screened a human brain cDNA library in l ZAPII (Stratagene) with the cDNA probes. The full length in pBluescript (Stratagene) was used as the template for PCR to prepare various constructs.
Abs
Rabbit antisera against SAD-B were raised against GST-SAD-B (aa 450-521; the anti-SAD-B Ab and aa 548-720; the anti-SCR2 Ab) and affinity purified as previously described . The polyclonal anti-CAST Ab was obtained as described (Takao-Rikitsu et al., 2004) . The polyclonal anti-NMDA receptor 2B (Chemicon), monoclonal synaptophysin (Chemicon), monoclonal anti-Myc (9E10) (Roche), monoclonal anti-Bassoon (StressGen), monoclonal anti-synaptotagmin I (WaKo Pure Chemical Industries, Osaka, Japan), and monoclonal anti-PSD-95/SAP90 (Transduction Laboratories) Abs were purchased from commercial sources.
Expression Vectors
Expression vectors were constructed in pGEX (Amersham Bioscience), pMALc2 (New England Biolabs), pEGFPC1 (CLONTECH Laboratories, Inc.), pCIneo-Myc, and pCAEGFP (Niwa et al., 1991) by standard molecular biological methods. The following constructs of SAD-B contain the following aa residues: EGFP-SAD-B-1 (aa 1-stop), EGFP-SAD-B-2 (aa 1-294), EGFP-SAD-B-3 (aa 1-400), EGFP-SAD-B-4 (aa 295-stop), EGFP-SAD-B-5 (aa 450-stop), EGFP-SAD-B-6 (aa 548-720), Myc-and MBP-kinase domain of SAD-B (aa 1-294). Myc-and EGFP-SAD-B-1 K63R and Myc-and MBP-kinase domain of SAD-B K63R and T189A/S193A were generated by site-directed mutagenesis with a GeneTailor Site-Directed Mutagenesis System (Invitrogen) according to the manufacturer's instructions. GST-and MBP-fusion proteins were produced and purified according to the manufacturer's instructions.
Recording mEPSC
Culture of hippocampal neurons was prepared as described previously (Hennou et al., 2003) . We used the lipofectamine2000 (Invitorgen) for the electrophysiological analysis. To measure the transfection efficiency of the lipofectamine2000 protocol, we measured the ratio of EGFP-expressing neuron when the EGFP-tagged protein was transfected to the neurons by the lipofectamine2000 protocol by the fluorescent microscope and FACS. 50%-60% of the neuron was EGFP detectable by a fluorescent microscope, and 80%-90% of the neurons was EGFP detectable by the FACS methods. For the mEPSC recording, the culture medium was exchanged for a saline solution containing 168 mM NaCl, 2.4 mM KCl, 2 mM or 10 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose, 10 mM HEPES, and 0.5 mM TTX (pH 7.3). Electrodes (2-4 MU tip resistance) were filled with the whole-cell pipette solution containing 120 mM K-acetate, 20 mM KCl, 0.1 mM CaCl 2 , 5 mM MgCl 2 , 0.2 mM EGTA, 5 mM ATP, and 10 mM HEPES (pH 7.3). Whole-cell recording configuration was achieved from the GFP-expressing neurons by using an EPC-7 amplifier (HEKA, Germany) and a Digidata 1200 acquisition board (Axon Instrument). Membrane potential was clamped at 260 mV, and signals were filtered at 10 kHz with gain set at 0.5 mV/pA for 40 s recording periods. In all instances, the cells were excluded from analysis if a leak current >300 pA was observed. Membrane resistance (R m ), series resistance (R s ), and membrane capacitance (C m ) were monitored. Only recordings with R m >100 MU and R s <20 MU were included for analysis. Mean R m , R s , and C m were not different (p > 0.05) among or within the cells in which comparisons were made. CNQX (50 mM), an AMPA receptor antagonist, was applied during a subset of recordings to determine that detected mEPSC events were AMPA receptor mediated. Measurement of the frequency and amplitude of mEPSC were performed for a period of 40 s. mEPSCs were detected by setting the amplitude threshold to background noise level 3 3. Data from each group were then averaged, and statistical significance was determined by Student's t test. p < 0.05 was considered to be statistically significant. All electrophysiological experiments were performed from at least two different platings of neurons from two different transfections.
SCG Neurons Culture, Immunocytochemistry, and Electrophysiological Recordings A culture of SCG neurons was prepared as described previously (Mochida et al., 1994) . For immunocytochemistry of SAD-B, Bassoon, and synaptophysin, we fixed SCG neurons cultured for 5-6 weeks and stained them as described above for hippocampal neurons. EPSP recording and injection of the recombinant proteins were performed as described previously (Mochida et al., 1994 (Mochida et al., , 1998a . Collected electrophysiological data with software written by the late L. Tauc (Centre National de la Recherche Scientifique, Gif-sur-Yvette, France) were analyzed with Origin (Microcal Software, Inc.). The peak amplitudes of EPSP were averaged. The resultant values were smoothed by an eight-point moving average algorithm and plotted against recording time with t = 0 indicting the presynaptic injection. For paired-pulse recordings, the membrane potential was held at 280 mV. For each neuron pair, three recordings were performed for each interval of two stimuli and then averaged.
To measure the RRP size, we puff applied 0.5 M sucrose to presynaptic neurons every 5 min (Mochida et al., 1998b) . The integral value of sucrose responses was averaged and normalized.
Phosphorylation Experiments
Various Myc-tagged SAD-B fragments overexpressed in HEK293 cells were immunoprecipitated with the anti-Myc Ab. The kinase activity of the immunoprecipitated proteins was measured by incubation at 30ºC for 30 min in a reaction buffer (50 ml) containing 50 mM Tris-HCl (pH 7.5), 0.1% Triton X-100, 1 mM dithiotheitol, 100 mM NaCl, 10 mM MgCl 2 , and 1 mCi of [g-32 P] ATP (Amersham). The reaction was stopped with 25 ml of 3 3 SDS-PAGE sample buffer. The supernatant was subjected to SDS-PAGE, followed by autoradiography and Coomassie Brilliant Blue staining.
Phosphorylation of MBP-SAD-B KD
wild and K63R was assayed under the same condition as described above. For analysis of RIM1 and Munc13-1 phosphorylation, various GST-fusion proteins of RIM1 and Munc13-1 indicated were incubated with MBP-SAD-B KD wild or K63R and analyzed as described above.
Other Procedures Subcellular fractionation of rat brain and solubilization of SAD-B from the P2 fraction were performed as described previously (Ohtsuka et al., 2002) . The methods for primary cultured neuron, transfection, immunocytochemistry, immunohistochemistry, immunoelectron microscopy, and immunoaffinity purification are described in the Supplemental Data.
Supplemental Data
The Supplemental Data for this article is available online at http:// www.neuron.org/cgi/content/full/50/2/261/DC1/.
